While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback